Acute Respiratory Distress Syndrome (ARDS) Market Analysis

Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The major complication in ARDS is marked by leakage of fluid into the lungs, making breathing difficult or impossible.
Out of total COVID-19 cases, the patients who are critically ill—very few and ranging from 1% to 4%—constitute the potential pool for ARDS.

The total incident population of ARDS in the 7MM was 799,872 in 2017.The incidence of ARDS in the United States was estimated to be 495,655 cases in 2017.

The United States showed the highest incident population of ARDS, as compared to EU5, and Japan. The US accounts for nearly 62% of total cases, for ARDS, in the 7MM countries.

For more details on Acute Respiratory Distress Syndrome (ARDS) Market Insights, Epidemiology, and Pipeline Analysis, visit: https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market